Cookies on AgBiotechNet

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

News Article

Cellectis S.A. and Celliance Collaborate on Mammalian Cell Lines Engineering

Cellectis S.A., the rational genome engineering company, and Celliance, a Serologicals Company have entered into a collaboration agreement under which CellianceTM will evaluate the Meganuclease Recombination System (MRS) technology of Cellectis for the development of a new generation of I-SceI meganuclease tagged host cell line, the generation and the promotion of efficient derivative cell lines for biopharmaceutical production.

Cellectis S.A., the rational genome engineering company, and Celliance, a Serologicals Company have entered into a collaboration agreement under which CellianceTM will evaluate the Meganuclease Recombination System (MRS) technology of Cellectis for the development of a new generation of I-SceI meganuclease tagged host cell line, the generation and the promotion of efficient derivative cell lines for biopharmaceutical production.
Financial terms and conditions were not disclosed.

Isabelle Pelletier-Bressac, Vice President Business Development of Cellectis commented "We do have several other evaluations going on with both CMOs and therapeutic proteins developers and we are very pleased of this new agreement with Celliance. Supported by strong internal results on meganuclease induced gene knock-in in CHO cells, we are convinced that the expertise and skills of Celliance. scientists relating to culture, development and use of host cell lines suitable for cellular protein production will lead to successful results". She added, "Indeed, in mammalian cells, the major advantages of our site-directed insertion system is a better control in the generation of producer cell lines, i.e. reproducibility, predictability, and consequently a gain of time in manufacturing."

Cellectis SA was founded in 1999, as a spin-off from the Institut Pasteur. It is applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-made Meganucleases for in vivo DNA interventions and also provides new tools for rational reverse genetics and targeted recombination. Cellectis develops Meganucleases that can induce unique site-directed double-strand breaks in a living cell, and can be used for biotechnological and therapeutical applications. The company is focusing on bringing "genome surgery" to clinic as a genuine new molecular medicine approach.

Celliance offers an expanding array of bioprocessing products and services including diagnostic products, contract research and manufacturing services (thru Celliance BioServices), and cell culture media supplements, including EX-CYTE®, the largest selling cell growth supplement, ProbuminTM, a proprietary line of bovine serum albumin and IncelligentTM, the Company's recombinant human insulin. It is also the world's leading provider of monoclonal antibodies for the blood typing industry. Celliance is a Serologicals company based in Atlanta, GA.

Article details

  • Author(s)
  • David Hemming
  • Date
  • 31 May 2005
  • Subject(s)
  • Genetic engineering/ modification